Published: July 06, 2017

CCTG Participating Sites and Investigators

As you may be aware, the National Clinical Trials Network (NCTN) of the US NCI is planning to launch a new Registration and Credential Repository (RCR) system and a Delegation of Tasks Log (DTL) in the coming months.  These systems are being developed to address requirements for ICH-GCP compliant conduct for NCTN trials, including documentation of qualifications, training, and study specific delegation of tasks.

Published: June 27, 2017
A patient of Dr. Booth’s in the CCTG Challenge Trial; ?>

A patient of Dr. Booth’s in the CCTG Challenge Trial follows her exercise prescription.

Clinical trials don’t always set out to prove whether drugs are effective. They can also test surgeries, radiation therapy, or even exercise. Dr. Christopher Booth was a CCTG research fellow in 2006 when results of a 30-year study in the United States noted that the nurses who exercised were less likely to contract colon cancer. Even more interesting was that those who contracted colon cancer and exercised were less likely to relapse. As a colon cancer specialist, Dr. Booth was intrigued and he suggested a trial that would attempt to further prove the American study’s findings.

Published: June 05, 2017
Canadian Cancer Trials Group at the American Society of Clinical Oncology Annual Meeting 2017

It has been another busy year for Canadian Cancer Trials Group at the American Society of Clinical Oncology Annual Meeting. This conference brings together oncology professionals from around the world to discuss state-of-the-art treatments, new therapies with the best minds in the field of cancer research.

CCTG is well represented on this world stage with three recognition awards, fifteen poster presentations, and four oral abstracts. See below for more details.

Published: May 30, 2017
The CCTG Accrual Utility is launched for member sites; ?>

The development team from left to right: Corey Willman, Teddy Brown, Patti O'Brien, David Judd, Heather Ritter

The CCTG Accrual Utility Team reached their final project milestone with the official launch of the Accrual Utility late last week. The customized, web-based application was developed by our in-house project team, who worked together to bring this anticipated solution to life.

Published: May 11, 2017
The trial is changing how brain cancer is treated in older patients around the world

Dr Christopher O’Callaghan knows the impact that glioblastoma, an aggressive form of brain cancer, can have on families. His father was diagnosed at a time when the only available treatment was radiation. But now, thanks to Dr O’Callaghan’s research with the Canadian Cancer Trials Group (CCTG), there are better treatment options for patients with glioblastoma.

Published: May 11, 2017
The trial is changing how brain cancer is treated in older patients around the world; ?>

Pictured here: Dr Chris O’Callaghan, senior investigator with Dr Janet Dancey, director, Canadian Cancer Trials Group

Dr Christopher O’Callaghan knows the impact that glioblastoma, an aggressive form of brain cancer, can have on families. His father was diagnosed at a time when the only available treatment was radiation. But now, thanks to Dr O’Callaghan’s research with the Canadian Cancer Trials Group (CCTG), there are better treatment options for patients with glioblastoma.

Published: May 08, 2017
CCS has renewed its commitment to CCTG through a major funding award of $23.5 million over 5 years.; ?>

From left to right: Janet Dancey, CCTG Director; Lynne Hudson, CCS President, and CEO; Richard Reznick, Dean of the Faculty of Health Sciences at Queen’s University.

The Canadian Cancer Society (CCS) has renewed its commitment to the Canadian Cancer Trials Group (CCTG) through a major funding award of $23.5 million over 5 years. This generous funding allows CCTG to continue its world-class cancer clinical trials research.

Published: April 05, 2017
Thanks to the Tragically Hip for their support of brain cancer research; ?>

Gord Sinclair, from left, and Rob Baker of The Tragically Hip, Janet Dancy, director of the Canadian Cancer Trials Group, and Lynne Hudson, president and CEO of the Canadian Cancer Society, at the unveiling of a plaque honouring The Hip.

The Canadian Cancer Society (CCS) recognized Kingston hometown heroes the Tragically Hip for their support of brain cancer research. A commemorative plaque was presented to the band in honour of their support for cancer clinical trials at the Canadian Cancer Trials Group (CCTG).

CCTG, housed at Queen’s University in Kingston, is supported by a core grant from the Canadian Cancer Society.

Published: March 02, 2017
iRECIST - immunotherapy Response Evaluation Criteria in Solid Tumours ; ?>

Immunotherapeutics trigger different response patterns in tumours than classic chemotherapy drugs.

A recent publication in The Lancet Oncology highlights the development, led by the RECIST Working Group, of iRECIST (immunotherapy Response Evaluation Criteria in Solid Tumours) consensus-based guideline, which addresses the novel characteristics of this new class of anticancer therapeutics, ensuring consistent trial design and data collection.

Published: February 09, 2017

Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the Canadian Clinical Trials Group Symptom Control Trial SC.23